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1. Introduction 
Leucoagglutinin (also named L-PHA) is the isolec- 
tin of PHA (phytohaemagglutinin from Phaseolus 
vulgaris - red kidney bean) practically devoid of 
haemagglutinating activity, but with high leucoagglu- 
tinating power and strong lymphocyte stimulating 
activity [ 11. The high haemagglutinating activity of 
PHA is concentrated in a second fraction (H-PHA) 
which is a mixture of isolectins with both mitogenic 
and red cell-agglutinating activities [2]. The molecule 
of leucoagglutinin is formed by four identical sub. 
units which interact with glycidic receptors on lym- 
phocytes [3,4]. The binding is specifically inhibited 
by N-acetylgalactosamine [5,6]. Leucoagglutinin in. 
teracts with human Tamm-Horsfall glycoprotein 
(T-H): the precipitin reaction is similar to a typical 
antigen-antibody reaction and is inhibited only by 
N-acetylgalactosamine [7]. After pronase digestion of 
T-H a glycopeptide can be isolated [8] which behaves 
as a powerful inhibitory hapten both in the precipitin 
reaction of T-H with leucoagglutinin and in lympho. 
cyte transformation induced by leucoagglutinin [9]. 
Here a haemagglutinating activity of leucoagglutinin 
is shown to appear after neuraminidase treatment of 
human erythrocytes. The specificity of desialylated 
receptors for leucoagglutinin was investigated by the 
hapten-inhibition test of haemagglutination. 
2. Experimental 
2.1. Materials 
Leucoagglutinin was from Pharmacia or was puri- 
fied from commercial PHA as in [7]. T-H was pre- 
pared from human pooled urine according to [lo]. 
Pronase digestion of T-H and purification of glyco. 
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peptide (T-H glycopeptide) were performed as de- 
tailed in [9]. Monosaccharides were from Sigma and 
neuraminidase from Behringwerke (1 U/ml). 
2.2. Neuraminidase treatment of human erythro- 
cytes 
Human erythrocytes were washed 4 times with 
PBS (20 mM sodium phosphate buffer (pH 7.4), 
containing 0.14 M NaCl). Cells (2 X lO*/ml) in 
PBS containing 1 mM CaClz were incubated with 
neuraminidase (0.015 U/ml) at 37°C with shaking. 
At the indicated times incubations were stopped by 
diluting cell suspensions with 50 vol. cold PBS. 
The neuraminidase-treated erythrocytes were imme- 
diately centrifuged and washed 4 times with PBS. 
2.3. Haemagglutination assay 
Haemagglutination tests were performed in U- 
shaped Greiner microtitre plates. Each well contained 
in 100 ~1 final vol. serial dilutions of leucoagglutinin 
and 50 ~1 untreated or treated erythrocyte suspen- 
sions (1.2%, v/v). When the effect of glycidic haptens 
was tested, they were added to the wells just before 
erythrocytes. All solutions and suspensions were in 
PBS containing bovine serum albumin at 15 pg/ml. 
Haemagglutination was evaluated visually after 3 h 
at room temperature. The concentration of leuco- 
agglutinin was determined by measuring the absor- 
bancy at 280 nm (A is&, 11.4). The minimal amount 
of leucoagglutinin required to agglutinate is defined 
as one unit of haemagglutinating activity (HU). 
3. Results and discussion 
Fig.1 reports the enhancement of haemagglutinat- 
ing activity of leucoagglutinin after neuraminidase 
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Table 1 
Effect of glycidic haptens on the haemagglutination of
neuraminidasc-treated human erythrocytes by 
leucoagglutinin 
Glycidic hapten Corm. Agglutination 
None 
T-H glycopeptide 
N-Acetyl-D-galactosamine 
N-Acetyl-D-glucosamine 
N-Acetyl-D-mannosamie 
D-Galactose 
D-Glucose 
D-Mannose 
L-Fucose 
- f 
3.2&M - 
25 mM - 
1OOmM + 
1OOmM + 
100mM + 
IOOmM + 
100mM + 
IOOmM + 
20 40 60 80 
~~-Methyls-D-galactoside 1OOmM + 
I-U-Methyl+D-galactoside IOOmM + 
*ims Of ne”rrm,“ldase treatment ,min, 1 -O-Methyl+Dglucoside 
1-GMethyl-p-Dglucoside 
100mM + 
100mM + 
Fig.1. The effect of neuraminidase treatment of human 
erythrocytes on the haemagglutinating activity of leuco- 
agglutinin. The erythrocytes used in the present experiment 
were group 0. The experimental conditions are in section 2. 
1-GMethyl-cl-D-mannoside 100mM + 
Human erythrocytes (group 0) were treated with neuramini- 
dase for 45 min. Leucoagglutinin was added at 2 HU/lOO j11 
(tinal volume in each well). The concentration of T-H glyco- 
peptide was calculated assuming mol. wt 4800 
treatment of human erythrocytes. The time course of 
neuraminidase treatment shows a very rapid exposure 
of leucoagglutinin receptors as assayed by the haem- 
agglutination test. After 45 min all receptors were 
unmasked. No differences were found with ery- 
throcytes from the 4 types of the ABO system. The 
identical agglut~ation before and after neur~~idase 
treatment of type A compared to types 0 and B 
indicates that the terminal N-acetylgalactosamine of 
the A blood group determinant isnot involved in the 
binding site for leucoagglutinin. 
The results of glycidic hapten-inhibition tests of 
haemagglutination areshown in table 1. The only 
monosacch~ide with i~ibitory activity was N-acetyl- 
~lactos~~e, active at 25 mM: T-H-~yco~ptide 
resulted in molar terms -10 OOO-times more inhibitory 
than N-acetylgalactosamine. Thesame ratio in the 
inhibitory activity of the two haptens was found in 
the precipitin reaction between T-H and leucoagglu- 
tinin 191. These data strongly suggest that an identical 
oligosaccharide structure is present on the surface 
of neur~~idase-treated human erythrocytes and in 
the glyco-moiety of T-H. It is well known that many 
lectins are able to interact with surface cell receptors 
after deletion of N-acetylneuraminic a id. Neura- 
minidase-treated rythrocytes and lymphocytes are 
agglutinated by peanut agglutinin [111 and neura- 
minidase-treated mouse spleen cells by soybean 
agglutinin [ 121 because galactosyl sites become x- 
posed, These results how that removal of N-acetyl- 
neuraminic acid from human erythrocytes unmasks 
N-acetylgalactosamine residues. 
The carbohydrate analysis of T-H glycopeptide 
gives 2.9% ~-acetylg~actosam~e m asured by the 
calorimetric method in [9], and 3.9% as measured 
by gas-liquid chromatography (unpublished). This 
means 1 residue/molecule, assuming mol. wt 4800 
for T-H glycopeptide (R. D. Marshall, personal com- 
munication). In spite of its low content in N-acetyl- 
galactosamine, the T-H glycopeptide shows the same 
inhibitory activity as the monosaccharide, at a con- 
centration 4 log lower. This suggests hat the affinity 
of the ligand for leucoagglutinin is strongly affected 
by a specific position of N-acetylgalactosamine i  the 
oligosaccharide structure. 
The high sensitivity of the haemagglutination test 
and the rapidity of its performance may by utilized in 
studies on the binding of leucoagglutinin to the cell 
receptors and in investigating the complexity of the 
carbohydrate specificity of this lectin. 
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